Cadila Healthcare gains after good Q2 result

Cadila Healthcare rose 2.19% to Rs 441 at 14:19 IST on BSE after consolidated net profit surged 40.56% to Rs 390.91 crore on 16.98% increase in total income to Rs 2483.19 crore in Q2 September 2015 over Q2 September 2014.

The result was announced yesterday, 22 October 2015, when the stock market was closed on account of Dussehra.

Meanwhile, the BSE Sensex was up 228.07 points, or 0.84%, to 27,515.73

On BSE, so far 2.24 lakh shares were traded in the counter, compared with an average volume of 42,807 shares in the past one quarter.

The stock hit a high of Rs 454.40 in intraday trade so far, which is record high for the stock. The stock hit a low of Rs 439.35 so far during the day. The stock hit a 52-week low of Rs 254.98 on 1 December 2014.

The stock had outperformed the market over the past one month till 21 October 2015, rising 8.31% compared with Sensex's 4.18% rise. The scrip had also outperformed the market in past one quarter, gaining 14.6% as against Sensex's 3.17% fall.

The large-cap company has an equity capital of Rs 102.37 crore. Face value per share is Re 1.

On consolidated basis, Cadila Healthcare's total operating income rose 17% to Rs 2460 crore in Q2 September 2015 over Q2 September 2014. The company's US business sales rose 25% to Rs 1004 crore in Q2 September 2015 over Q2 September 2014.

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News